Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins αvβ3, α4β1, and α5β1

Journal of Biological Chemistry

Volumn 290, Issue 1, 2015, Pages 259-271

  Fujita, Masaaki ^a,c   Zhu, Kan ^a   Fujita, Chitose K ^c   Zhao, Min ^a   Lam, Kit S ^a   Kurth, Mark J ^b   Takada, Yoko K ^a   Takada, Yoshikazu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Kitano Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CATALYST ACTIVITY; CELL MEMBRANES; CELL PROLIFERATION; CHEMICAL ACTIVATION; FIBER OPTIC SENSORS; GLYCOPROTEINS;

ALLOSTERIC MECHANISMS; CONFORMATIONAL CHANGE; DIRECT BINDINGS; DOCKING SIMULATIONS; INTEGRIN ACTIVATION; LIGAND-BINDING SITES; PHOSPHOLIPASE A2; SIGNALING PATHWAYS;

CELL SIGNALING;

FIBRONECTIN; PHOSPHOLIPASE A2 GROUP II; PHOSPHOLIPASE A2 INHIBITOR; PHOSPHOLIPASE A2 TYPE IIA; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR; ENZYME INHIBITOR; INTEGRIN ALPHAVBETA1; PEPTIDE; PROTEIN BINDING; RECOMBINANT PROTEIN;

ANIMAL CELL; ARTICLE; BINDING SITE; CATALYSIS; CELL FREE SYSTEM; CELL SURFACE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; INTRACELLULAR SIGNALING; LIGAND BINDING; MOLECULAR DOCKING; NONHUMAN; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN MOTIF; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHO CELL LINE; CRICETULUS; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; K-562 CELL LINE; METABOLISM; MOLECULAR GENETICS; MOLECULAR MODEL; PATHOLOGY; SEQUENCE ALIGNMENT; SYNTHESIS;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CHO CELLS; CRICETULUS; ENZYME INHIBITORS; ESCHERICHIA COLI; GENE EXPRESSION REGULATION; GROUP II PHOSPHOLIPASES A2; HUMANS; INFLAMMATION; INTEGRIN ALPHA4BETA1; INTEGRIN ALPHAVBETA3; K562 CELLS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN BINDING; RECEPTORS, VITRONECTIN; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION;

EID: 84920518141     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.579946     Document Type: Article

References (50)

1. Vadas, P., Stefanski, E., and Pruzanski, W. (1985) Characterization of extracellular phospholipase A2 in rheumatoid synovial fluid. Life Sci. 36, 579-587
2. Jaross, W., Eckey, R., and Menschikowski, M. (2002) Biological effects of secretory phospholipase A2 group IIA on lipoproteins and in atherogenesis. Eur J. Clin. Invest. 32, 383-393
3. Niessen, H. W., Krijnen, P. A., Visser, C. A., Meijer, C. J., and Erik Hack, C. (2003) Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc. Res. 60, 68-77
4. Jiang, J., Neubauer, B. L., Graff, J. R., Chedid, M., Thomas, J. E., Roehm, N. W., Zhang, S., Eckert, G. J., Koch, M. O., Eble, J. N., and Cheng, L. (2002) Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am. J. Pathol. 160, 667-671
5. Dong, Q., Patel, M., Scott, K. F., Graham, G. G., Russell, P. J., and Sved, P. (2006) Oncogenic action of phospholipase A2 in prostate cancer. Cancer Lett. 240, 9-16
6. Sved, P., Scott, K. F., McLeod, D., King, N. J., Singh, J., Tsatralis, T., Nikolov, B., Boulas, J., Nallan, L., Gelb, M. H., Sajinovic, M., Graham, G. G., Russell, P. J., and Dong, Q. (2004) Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res. 64, 6934-6940
7. Tada, K., Murakami, M., Kambe, T., and Kudo, I. (1998) Induction of cyclooxygenase-2 by secretory phospholipases A2 in nerve growth factor-stimulated rat serosal mast cells is facilitated by interaction with fibroblasts and mediated by a mechanism independent of their enzymatic functions. J. Immunol. 161, 5008-5015
8. Triggiani, M., Granata, F., Balestrieri, B., Petraroli, A., Scalia, G., Del Vecchio, L., and Marone, G. (2003) Secretory phospholipases A2 activate selective functions in human eosinophils. J. Immunol. 170, 3279-3288
9. Lambeau, G., Ancian, P., Barhanin, J., and Lazdunski, M. (1994) Cloning and expression of a membrane receptor for secretory phospholipases A2. J. Biol. Chem. 269, 1575-1578
10. Nicolas, J. P., Lambeau, G., and Lazdunski, M. (1995) Identification of the binding domain for secretory phospholipases A2 on their M-type 180-kDa membrane receptor. J. Biol. Chem. 270, 28869-28873
11. Cupillard, L., Mulherkar, R., Gomez, N., Kadam, S., Valentin, E., Lazdunski, M., and Lambeau, G. (1999) Both group IB and group IIA secreted phospholipases A2 are natural ligands of the mouse 180-kDa M-type receptor. J. Biol. Chem. 274, 7043-7051
12. Hynes, R. O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687
13. Takada, Y., Ye, X., and Simon, S. (2007) The integrins. Genome Biol. 8, 215
14. Saegusa, J., Akakura, N., Wu, C. Y., Hoogland, C., Ma, Z., Lam, K. S., Liu, F. T., Takada, Y. K., and Takada, Y. (2008) Proinflammatory secretory phospholipase A2 type IIA binds to integrins αvβ3 and α4β1 and induces proliferation of monocytic cells in an integrin-dependent manner. J. Biol. Chem. 283, 26107-26115
15. Ye, L., Dickerson, T., Kaur, H., Takada, Y. K., Fujita, M., Liu, R., Knapp, J. M., Lam, K. S., Schore, N. E., Kurth, M. J., and Takada, Y. (2013) Identification of inhibitors against interaction between proinflammatory sPLA2-IIA protein and integrin αvβ3. Bioorg. Med. Chem. Lett. 23, 340-345
16. Zhu, J., Zhu, J., and Springer, T. A. (2013) Complete integrin headpiece opening in eight steps. J. Cell Biol. 201, 1053-1068
17. Xiong, J. P., Mahalingham, B., Alonso, J. L., Borrelli, L. A., Rui, X., Anand, S., Hyman, B. T., Rysiok, T., Müller-Pompalla, D., Goodman, S. L., and Arnaout, M. A. (2009) Crystal structure of the complete integrin αVβ3 ectodomain plus an α/β transmembrane fragment. J. Cell Biol. 186, 589-600
18. Fujita, M., Takada, Y. K., and Takada, Y. (2012) Integrins αvβ3 and α4β1 act as coreceptors for fractalkine, and the integrin-binding defective mutant of fractalkine is an antagonist of CX3CR1. J. Immunol. 189, 5809-5819
19. Fujita, M., Takada, Y. K., and Takada, Y. (2014) The chemokine fractalkine can activate integrins without CX3CR1 through direct binding to a ligand-binding site distinct from the classical RGD-binding site. PLoS ONE 9, e96372
20. Blystone, S. D., Graham, I. L., Lindberg, F. P., and Brown, E. J. (1994) Integrin αvβ3 differentially regulates adhesive and phagocytic functions of the fibronectin receptor α5β1. J. Cell Biol. 127, 1129-1137
21. Takagi, J., Erickson, H. P., and Springer, T. A. (2001) C-terminal opening mimics "inside-out" activation of integrin α5β1. Nat. Struct. Biol. 8, 412-416
22. Yokoyama, K., Zhang, X. P., Medved, L., and Takada, Y. (1999) Specific binding of integrin αvβ3 to the fibrinogen γ and αE chain C-terminal domains. Biochemistry 38, 5872-5877
23. Zhang, X. P., Kamata, T., Yokoyama, K., Puzon-McLaughlin, W., and Takada, Y. (1998) Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin αvβ3. J. Biol. Chem. 273, 7345-7350
24. Mori, S., Wu, C. Y., Yamaji, S., Saegusa, J., Shi, B., Ma, Z., Kuwabara, Y., Lam, K. S., Isseroff, R. R., Takada, Y. K., and Takada, Y. (2008) Direct binding of integrin αvβ3 to FGF1 plays a role in FGF1 signaling. J. Biol. Chem. 283, 18066-18075
25. Yokoyama, K., Erickson, H. P., Ikeda, Y., and Takada, Y. (2000) Identification of amino acid sequences in fibrinogen γ-chain and tenascin C C-terminal domains critical for binding to integrin αvβ3. J. Biol. Chem. 275, 16891-16898
26. Nevalainen, T. J., Aho, H. J., and Peuravuori, H. (1994) Secretion of group 2 phospholipase A2 by lacrimal glands. Invest. Ophthalmol. Vis. Sci. 35, 417-421
27. Qu, X. D., and Lehrer, R. I. (1998) Secretory phospholipase A2 is the principal bactericide for staphylococci and other gram-positive bacteria in human tears. Infect. Immun. 66, 2791-2797
28. Birts, C. N., Barton, C. H., and Wilton, D. C. (2010) Catalytic and non-catalytic functions of human IIA phospholipase A2. Trends Biochem. Sci 35, 28-35
29. Saari, K. M., Aho, V., Paavilainen, V., and Nevalainen, T. J. (2001) Group II PLA2 content of tears in normal subjects. Invest. Ophthalmol. Vis. Sci. 42, 318-320
30. Aho, H. J., Saari, K. M., Kallajoki, M., and Nevalainen, T. J. (1996) Synthesis of group II phospholipase A2 and lysozyme in lacrimal glands. Invest. Ophthalmol. Vis. Sci. 37, 1826-1832
31. Yamaji, S., Saegusa, J., Ieguchi, K., Fujita, M., Mori, S., Takada, Y. K., and Takada, Y. (2010) A novel fibroblast growth factor-1 (FGF1) mutant that acts as an FGF antagonist. PLoS ONE 5, e10273
32. Mori, S., and Takada, Y. (2013) Crosstalk between fibroblast growth factor (FGF) receptor and integrin through direct integrin binding to FGF and resulting integrin-FGF-FGFR ternary complex formation. Med. Sci. 1, 20-36
33. Mori, S., Tran, V., Nishikawa, K., Kaneda, T., Hamada, Y., Kawaguchi, N., Fujita, M., Saegusa, J., Takada, Y. K., Matsuura, N., Zhao, M., and Takada, Y. (2013) A dominant-negative FGF1 mutant (the R50E mutant) suppresses tumorigenesis and angiogenesis. PLoS ONE 8, e57927
34. Saegusa, J., Yamaji, S., Ieguchi, K., Wu, C. Y., Lam, K. S., Liu, F. T., Takada, Y. K., and Takada, Y. (2009) The direct binding of insulin-like growth factor-1 (IGF-1) to integrin αvβ3 is involved in IGF-1 signaling. J. Biol. Chem. 284, 24106-24114
35. Fujita, M., Ieguchi, K., Davari, P., Yamaji, S., Taniguchi, Y., Sekiguchi, K., Takada, Y. K., and Takada, Y. (2012) Cross-talk between integrin α6β4 and insulin-like growth factor-1 receptor (IGF1R) through direct α6β4 binding to IGF1 and subsequent α6β4-IGF1-IGF1R ternary complex formation in anchorage-independent conditions. J. Biol. Chem. 287, 12491-12500
36. Fujita, M., Ieguchi, K., Cedano-Prieto, D. M., Fong, A., Wilkerson, C., Chen, J. Q., Wu, M., Lo, S. H., Cheung, A. T., Wilson, M. D., Cardiff, R. D., Borowsky, A. D., Takada, Y. K., and Takada, Y. (2013) An integrin binding-defective mutant of insulin-like growth factor-1 (R36E/R37E IGF1) acts as a dominant-negative antagonist of the IGF1 receptor (IGF1R) and suppresses tumorigenesis but still binds to IGF1R. J. Biol. Chem. 288, 19593-19603
37. Fujita, M., Takada, Y. K., and Takada, Y. (2013) Insulin-like growth factor (IGF) signaling requires αvβ3-IGF1-IGF type 1 receptor (IGF1R) ternary complex formation in anchorage independence, and the complex formation does not require IGF1R and Src activation. J. Biol. Chem. 288, 3059-3069
38. Ieguchi, K., Fujita, M., Ma, Z., Davari, P., Taniguchi, Y., Sekiguchi, K., Wang, B., Takada, Y. K., and Takada, Y. (2010) Direct binding of the EGF-like domain of neuregulin-1 to integrins (αvβ3 and α6β4) is involved in neuregulin-1/ErbB signaling. J. Biol. Chem. 285, 31388-31398
39. Xiong, J. P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M., Goodman, S. L., and Arnaout, M. A. (2002) Crystal structure of the extracellular segment of integrin α Vβ3 in complex with an Arg-Gly-Asp ligand. Science 296, 151-155
40. Xiao, T., Takagi, J., Coller, B. S., Wang, J. H., and Springer, T. A. (2004) Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature 432, 59-67
41. Du, X. P., Plow, E. F., Frelinger, A. L., 3rd, O'Toole, T. E., Loftus, J. C., and Ginsberg, M. H. (1991) Ligands "activate" integrin αIIbβ3 (platelet GPIIb-IIIa). Cell 65, 409-416
42. Legler, D. F., Wiedle, G., Ross, F. P., and Imhof, B. A. (2001) Superactivation of integrin αvβ3 by low antagonist concentrations. J. Cell Sci. 114, 1545-1553
43. Hu, D. D., White, C. A., Panzer-Knodle, S., Page, J. D., Nicholson, N., and Smith, J. W. (1999) A new model of dual interacting ligand binding sites on integrin αIIbβ3. J. Biol. Chem. 274, 4633-4639
44. Cierniewski, C. S., Byzova, T., Papierak, M., Haas, T. A., Niewiarowska, J., Zhang, L., Cieslak, M., and Plow, E. F. (1999) Peptide ligands can bind to distinct sites in integrin αIIbβ3 and elicit different functional responses. J. Biol. Chem. 274, 16923-16932
45. Luo, B. H., Carman, C. V., and Springer, T. A. (2007) Structural basis of integrin regulation and signaling. Annu. Rev. Immunol. 25, 619-647
46. Luque, A., Gómez, M., Puzon, W., Takada, Y., Sánchez-Madrid, F., and Cabañas, C. (1996) Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common β 1 chain. J. Biol. Chem. 271, 11067-11075
47. Mould, A. P., Barton, S. J., Askari, J. A., McEwan, P. A., Buckley, P. A., Craig, S. E., and Humphries, M. J. (2003) Conformational changes in the integrin β A domain provide a mechanism for signal transduction via hybrid domain movement. J. Biol. Chem. 278, 17028-17035
48. Xiong, J. P., Stehle, T., Diefenbach, B., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Goodman, S. L., and Arnaout, M. A. (2001) Crystal structure of the extracellular segment of integrin αVβ3. Science 294, 339-345
49. Bradley, J. D., Dmitrienko, A. A., Kivitz, A. J., Gluck, O. S., Weaver, A. L., Wiesenhutter, C., Myers, S. L., and Sides, G. D. (2005) A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J. Rheumatol. 32, 417-423
50. Bowton, D. L., Dmitrienko, A. A., Israel, E., Zeiher, B. G., and Sides, G. D. (2005) Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma. J Asthma 42, 65-71